Evidence for immunopathogenesis

Handbook of Multiple Sclerosis, Third Edition

Volumn , Issue , 2001, Pages 163-192

  Traugott, Ute ^a  

^a BRONX LEBANON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0037615077     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (115)

1. Charcot J-M. Histologie de la sclerose en plaques, Gaz Hop (Paris) 1868; 41:554.
2. Traugott U. Evidence for immunopathogenesis. In: Cook, S, ed. Handbook of Multiple Sclerosis, 2nd ed. New York: Marcel Dekker, 1996, pp 157.
3. Janeway CA, Travers P. Autoimmunity: Responses to self antigens. In: Janeway CA, Travers P, eds. Immunobiology: The Immune System in Health and Disease, 2nd ed. New York: Garland, 1996, p 11:01.
4. Cope AP. Regulation of autoimmunity by proinflamamtory cytokines. Curr Opin Immunol 1998; 10:669.
5. Ransohoff RM. Mechanisms of inflammation in MS tissue: Adhesion molecules and chemokines. J Neuroimmunol. 1999; 98:57.
6. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1313:13.
7. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 8538:893.
8. Rose NR, Bona C. Defining criteria for autoimmune disease (Witebsky’s postulates revisisted). Immunol. Today 1993; 14:426.
9. Traugott U, Scheinberg LC. Comparison between lymphocyte abnormalities in blood and cerebrospinal fluid and the immunopathology of lesions in multiple sclerosis and experimental autoimmune encephalomyelitis. In: Lowenthal A, Raus J, eds. Cellular and Humoral Immunological Components of Cerebrospinal Fluid in Multiple Sclerosis. New York: Plenum, 1987, p 17.
10. Bongioanni P, Fioretti C, Vanacore R, Bianchi F, Lombardo F, Ambrogi F, Meucci G. Lymphocyte subsets in multiple sclerosis: A study with two-colour fluorescence analysis. J Neurol Sci 1996; 139:71.
11. Calopa M, Bas J, Mestre M, Arbizu T, Peres J, Buendia E. T cell subsets in multiple sclerosis: A serial study. Acta Neurol Scand 1995; 92:361.
12. Oksaranta O, Tarvonen S, Ilonen J, Poikonen K, Reunanen M, Panelius M, Salonen R. Tcell subpopulations in the cerebrospinal fluid and peripheral blood of patients with multiple sclerosis: A follow-up study. Neurology 1996; 47:1542.
13. Ferrante P, Fusi ML, Saresella M, Caputo D, Biasin M, Trabattoni D, Salvaggio A, Clerici E, de-Vries JE, Aversa G, Cazzullo CL, Clerici M. Cytokine production and surface marker expression in acute and stable multiple sclerosis: Altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J Immunol 1998; 160:1514.
14. Liedtke W, Meyer G, Faustmann PM, Warnatz H, Raine CS. Clonal expansion and decreased occurrence of peripheral blood gamma delta T cells of the V delta 2J delta 3 lineage in multiple sclerosis patients. Int Immunol 1997; 9:1031.
15. Michalowska-Wender G, Nowak J, Wender M. Gamma/delta T cell receptor genes rearrangement in the blood and brain of multiple sclerosis patients. A preliminary study. Folia Neuropathol 1998; 36:1.
16. Richert JR, Robinson ED, Johnson AH, Cohn ML, McFarland HF, Hurley CK. Myelin basic protein-reactive human T-cell clones: Stimulation by diverse microbial antigens. Ann NY Acad Sci 1995; 756:319.
17. Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol 1998; 86:123.
18. Matusevicius D, Kivisakk P, Navikas V, Soderstrom M, Fredrikson S, Link H. Interleukin-12 and perforin mRNA expression is augmented in blood mononuclear cells in multiple sclerosis. Can J Immunol 1998; 47:582.
19. Kraus J, Oschmann P, Engelhardt B, Schiel C, Hornig C, Bauer R, Kern A, Traupe H, Dorndorf W. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol Scand 1998; 98:102.
20. Mossner R, Fassbender K, Kuhnen J, Schwartz A, Hennerici M. Vascular cell adhesion molecule- A new approach to detect endothelial cell activation in MS and encephalitis in vivo. Acta Neurol Scand 1996; 93:118.
21. Giovannoni G, Thorpe JW, Kidd D, Kendall BE, Moseley IF, Thompson AJ, Keir G, Miller DH, Feldmann M, Thompson EJ. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 1996; 60: 20.
22. Filaci G, Contini P, Brenci S, Gazzola P, Lanza L, Scudeletti M, Indiveri F, Mancardi GL, Puppo F. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. Hum Immunol 1997; 54:54.
23. Zipp F, Faber E, Sommer N, Muller C, Dichgans J, Krammer PH, Martin R, Weller M. CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis: No differences from normal individuals and no relation to HLA-DR2. J Neuroimmunol 1998; 81:168.
24. Ohsako S, Elkon KB. Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis. Cell Death Differ 1999; 6:13.
25. Bansil S, Holtz CR, Cook SD, Rohowsky-Kochan C. Serum sAPO-1/Fas levels in multiple sclerosis. Acta Neurol Scand 1997; 95:208.
26. Zipp F, Martin R, Lichtenfels R, Roth W, Dichgans J, Krammer PH, Weller M. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J Immunol 1997; 159:2108.
27. Zipp F, Otzelberger K, Dichgans J, Martin R, Weller M. Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis. J Neuroimmunol 1998; 86:151.
28. Windhagen A, Maniak S, Gebert A, Ferger I, Heidenreich D. Costimulatory molecules B7-1 and B7-2 on CSF cells in multiple sclerosis and optic neuritis. J Neuroimmunol 1999; 96: 112.
29. Santiago E, Perez-Mediavilla LA, Lopez-Moratalla N. The role of nitric oxide in the pathogenesis of multiple sclerosis. J Physiol Biochem 1998; 54:229.
30. Lopez-Moratalla N, Gonzalez A, Aymerich MS, Lopez-Zabalza MJ, Pio R, de-Castro P, Santiago E. Monocyte inducible nitric oxide synthase in multiple sclerosis: Regulatory role of nitric oxide. Nitric Oxide 1997; 1:95.
31. Giovannoni G. Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis. Mult Scler 1998; 4:27.
32. Yacyshyn B, Meddings J, Sadowski D, Bowe-Yacyshyn MB. Multiple sclerosis patients have peripheral blood CD45RO + B cells and increased intestinal permeability. Dig Dis Sci 1996; 41:2493.
33. Zaffaroni M, Stampins LG, Ghezzi A, Baldini SM, Zibetti A. In vitro cytokine, sCD23 and IgG secretion in multiple sclerosis. J Neuroimmunol 1995; 61:1.
34. Calabresi PA, Fields NS, Farnon EC, Frank JA, Bash CN, Kawanashi T, Maloni H, Jacobson S, McFarland HF. ELI-spot of Th-1 cytokine secreting PBMCs in multiple sclerosis: Correlation with MRI lesions. J Neuroimmunol 1998; 85:212.
35. Balashov KE, Olek MJ, Smith DR, Khoury SJ, Weiner HL. Seasonal variation of interferongamma production in progressive multiple sclerosis. Ann Neurol 1998; 44:824.
36. Philippe J, Debruyne J, Leroux-Roels G, Willems A, Dereuck J. In vitro TNF-alpha, IL-2 and IFN-gamma production as markers of relapses in multiple sclerosis. Clin Neurol Neurosurg 1996; 98:286.
37. Chofflon M, Roth S, Juillard C, Paunier AM, Juillard P, Degroote D, Grau GE. Tumor necrosis factor production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis. Eur Cytokine Net 1997; 8:253.
38. Matusevicius D, Navikas V, Soderstrom M, Xiao BG, Haglund M, Fredrikson S, Link H. Multiple sclerosis: the proinflammatory cytokines lymphotoxin-alpha and tumour necrosis factor-alpha are upregulated in cerebrospinal fluid mononuclear cells. J Neuroimmunol 1996; 66:115.
39. Navikas V, Martin C, Matusevicius D, Soderstrom M, Fredrikson S, Link H. Soluble CD30 levels in plasma and cerebrospinal fluid in multiple sclerosis, HIV infection and other nervous system diseases. Acta Neurol Scand 1997; 95:99.
40. Comabella M, Balashov K, Issazadeh S, Smith D, Weiner HL, Khoury SJ. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998; 102:671.
41. Navikas V, Link J, Palasik W, Soderstrom M, Fredrikson S, Olsson T, Link H. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand J Immunol 1995; 41:171.
42. Monteyne P, Van-Laere V, Marichal R, Sindic CJ. Cytokine mRNA expression in CSF and peripheral blood mononuclear cells in multiple sclerosis: Detection by RT-PCR without in vitro stimulation. J Neuroimmunol 1997; 80:137.
43. Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998; 187:537.
44. Metz LM, McGuinness SD, Harris C. Urinary tract infections may trigger relapse in multiple sclerosis. Axone 1998; 19:67.
45. Kivisakk P, Teleshova N, Ozenci V, Huang Y, Matusevicius D, Fredrikson S, Soderstrom M, Link H. No evidence for elevated numbers of mononuclear cells expressing MCP-1 and RANTES mRNA in blood and CSF in multiple sclerosis. J Neuroimmunol 1998; 91:108.
46. Lee MA, Stabler JP, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: A longitudinal clinical and MRI study. Brain 1999; 122:191.
47. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999; 96:6873.
48. Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997; 58:52.
49. Karni A, Bakimer-Kleiner R, Abramsky O, Ben-Nun A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol 1999; 56:311.
50. Rawes JA, Calabrese VP, Khan OA, DeVries GH. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases. Mult Scler 1997; 3:363.
51. Smith ME. Phagocytosis of myelin in demyelinative disease: A review. Neurochem Res 1999; 24:261.
52. Monteyne P, Guillaume B, Sindic CJ. B7-1 (CD80), B7-2 (CD86), interleukin-12 and transforming growth factor-beta mRNA expression in CSF and peripheral blood mononuclear cells from multiple sclerosis patients. J Neuroimmunol 1998; 91:198.
53. Cross AH, Manning PT, Keeling RM, Schmidt RE, Mishko TP. Peroxinitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 1998; 88: 45.
54. Rollnik JD, Sindern E, Schweppe C, Malin JP. Biologically active TGF-beta 1 is increased in cerebrospinal fluid while it is reduced in serum in multiple sclerosis patients. Acta Neurol Scand 1997; 96:101.
55. Frederiksen JL, Sindic CJ. Intrathecal synthesis of virus-specific oligoclonal IgG, and of free kappa and free lambda oligoclonal bands in acute monosymptomatic optic neuritis: Comparison with brain MRI. Mult Scler 1998; 4:22.
56. Dybwad A, Flrre O, Sioud M. Probing for cerebrospinal fluid antibody specificities by a panel of random peptide libraries. Autoimmunity 1997; 25:85.
57. Luxton RW, Leman A, Holzel H, Harvey P, Wilson J, Kocen R, Morgan-Hughes J, Miller DH, Compston A, Thompson EJ. Affinity of antigen-specific IgG distinguishes multiple sclerosis from encephalitis. J Neurol Sci 1995; 132:11.
58. Ristori G, Montesperelli C, Uccelli A, Giunti D, Buttinelli C, Bomprezzi R, Mancardi GL, Salvetti M. A major influence of the T cell receptor repertoire as compared to antigen processing-presentation in the selection of myelin basic protein epitopes in multiple sclerosis. J Neuroimmunol 1999; 96:241.
59. Burns J, Bartholomew B, Lobo S. Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis. Ann Neurol 1999; 45:33.
60. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients: A marker of activated/memory T cells [published erratum appears in J Clin Invest 1998 Apr 1;101(7):1542], J Clin Invest 1998; 101:725.
61. Tranquill LR, Skinner E, Campagnoni C, Vergelli M, Hemmer B, Muraro P, Martin R, McFarland HF, Campagnoni AT, Voskuhl RR. Human T lymphocytes specific for the immunodominant 83-99 epitope of myelin basic protein: Recognition of golli MBP HOG 7. J Neurosci Res 1996; 45:820.
62. Lovett-Racke AE, Martin R, McFarland HF, Racke MK, Utz U. Longitudinal study of myelin basic protein-specific T-cell receptors during the course of multiple sclerosis. J Neuroimmunol 1997; 78:162.
63. Markovic-Plese S, Fukaura H, Zhang J, al-Sabbagh A, Southwood S, Sette A, Kuchroo VK, Hafler DA. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J Immunol 1995; 155:982.
64. Correale J, Rojany M, Weiner LP. Human CD8+ TCR-alpha beta(+) and TCR-gamma delta(+) cells modulate autologous autoreactive neuroantigen-specific CD4+ T-cells by different mechanisms. J Neuroimmunol 1997; 80:47.
65. Burger D, Lou J, Dayer JM, Grau GE. Both soluble and membrane-associated TNF activate brain microvascular endothelium: relevance to multiple sclerosis. Mol Psychiatry 1997; 2:113.
66. Verbeek MM, Westphal JR, Ruiter DJ, de-Waal RM. T lymphocyte adhesion to human brain pericytes is mediated via very late antigen-4/vascular cell adhesion molecule-1 interactions. J Immunol 1995; 154:5876.
67. Vora AJ, Kidd D, Miller DH, Perkin GD, Hughes RA, Ellis BA, Dumonde DC, Brown KA. Lymphocyte-endothelial cell interactions in multiple sclerosis: Disease specificity and relationship to circulating tumour necrosis factor-alpha and soluble adhesion molecules. Mult Scler 1997; 3:171.
68. Frigerio S, Gelati M, Ciusani E, Corsini E, Dufour A, Massa G, Salmaggi A. Immunocompetence of human microvascular brain endothelial cells: Cytokine regulation of IL-1beta, MCP-1, IL-10, sICAM-1 and sVCAM-1. J Neurol 1998; 245:727.
69. Gasque P, Jones J, Singhrao SK, Morgan B. Identification of an astrocyte cell population from human brain that expresses perforin, a cytotoxic protein implicated in immune defense. J Exp Med 1998; 187:451.
70. Barnes DA, Huston M, Holmes R, Benveniste EN, Yong VW, Scholz P, Perez HD. Induction of RANTES expression by astrocytes and astrocytoma cell lines. J Neuroimmunol 1996; 71:207.
71. Saas P, Boucraut J, Quiquerez AL, Schnuriger V, Perrin G, Desplat-Jego S, Bernard D, Walker PR, Dietrich PY. CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: A key role in brain inflammation? J Immunol 1999; 162:2326.
72. Cammer W, Zhang H. Maturation of oligodendrocytes is more sensitive to TNF alpha than is survival of precursors and immature oligodendrocytes. J Neuroimmunol 1999; 97:37.
73. D’Souza SD, Alinauskas KA, Antel JP. Ciliary neurotrophic factor selectively protects human oligodendrocytes from tumor necrosis factor-mediated injury. J Neurosci Res 1996; 43: 289.
74. Scolding NJ, Morgan BP, Compston DA. The expression of complement regulatory proteins by adult human oligodendrocytes. J Neuroimmunol 1998; 84:69.
75. Dangond F, Windhagen A, Groves CJ, Hafler DA. Constitutive expression of costimulatory molecules by human microglia and its relevance to CNS autoimmunity. J Neuroimmunol 1997; 76:132.
76. Washington RA, Becher B, Balabanov R, Antel J, Dore-Duffy P. Expression of the activation marker urokinase plasminogen-activator receptor in cultured human central nervous system microglia. J Neurosci Res 1996; 45:392.
77. Chabot S, Williams G, Yong VW. Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferon beta-1b. J Clin Invest 1997; 100:604.
78. Tan J, Town T, Paris D, Placzek A, Parker T, Crawford F, Yu H, Humphrey J, Mullan M. Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis. J Neuroimmunol 1999; 97:77.
79. Lassmann H. Neuropathology in multiple sclerosis: new concepts. Mult Scler 1998; 4:93.
80. Trapp B, Peterson J, Ransohoff R, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278.
81. De-Groot CJ, Montagne L, Barten AD, Sminia P, Van-Der-Valk P. Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures. J Neuropathol Exp Neurol 1999; 58:174.
82. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, Van-der-Valk P, De-Groot CJ. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol Berl 1997; 94:590.
83. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998; 84:238.
84. Gveric D, Kaltschmidt C, Cuzner ML, Newcombe J. Transcription factor NF-kappaB and inhibitor I kappaBalpha are localized in macrophages in active multiple sclerosis lesions. J Neuropathol Exp Neurol 1998; 57:168.
85. Masdeu JC, Moreira J, Tras S, Visinteiner P, Cavaliere R, Grundman M. The open ring. A new imaging sign in demyelinating disease. J Neuroimaging 1996; 6:104.
86. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML, Hafler DA. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995; 182:1985.
87. Cannella B, Sizing ID, Benjamin CD, Browning JL, Raine CS. Antibodies to lymphotoxin alpha (LT alpha) and LT beta recognize different glial cell types in the central nervous system. J Neuroimmunol 1997; 78:172.
88. Raine CS, Bonetti B, Cannella B. Multiple sclerosis: Expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque. Rev Neurol Paris 1998; 154:577.
89. Schluesener HJ, Seid K, Kretzschmar J, Meyermann R. Leukocyte chemotactic factor, a natural ligand to CD4, is expressed by lymphocytes and microglial cells of the MS plaque. J Neurosci Res 1996; 44:606.
90. Bo L, Peterson JW, Mork S, Hoffman PA, Gallatin WM, Ransohoff RM, Trapp BD. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55:1060.
91. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: In situ evidence for antibody-and complement-mediated demyelination. Ann Neurol 1998; 43:465.
92. Vladimirova O, O’Connor J, Cahill A, Alder H, Butunoi C, Kalman B. Oxidative damage to DNA in plaques of MS brains. Mult Scler 1998; 4:413.
93. Cuzner ML, Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 1999; 94:1.
94. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998; 21:75.
95. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan C. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: An immunohistochemical and in situ hybridization study. J Neuroimmunol 1998; 86:20.
96. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103:807.
97. Battistini L, Fischer FR, Raine CS, Brosnan CF. CD1b is expressed in multiple sclerosis lesions. J Neuroimmunol 1996; 67:145.
98. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, Kolbeck R, Hoppe E, Oropeza-Wekerle RL, Bartke I, Stadelmann C, Lassmann H, Wekerle H, Hohlfeld R. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999; 189:865.
99. Battistini L, Salvetti M, Ristori G, Falcone M, Raine CS, Brosnan CF. Gamma delta T cell receptor analysis supports a role for HSP 70 selection of lymphocytes in multiple sclerosis lesions. Mol Med 1995; 1:554.
100. Hvas J, McLean C, Justesen J, Kannourakis G, Steinman L, Oksenberg JR, Bernard CC. Perivascular T cells express the pro-inflammatory chemokine RANTES mRNA in multiple sclerosis lesions. Scand J Immunol 1997; 46:195.
101. Gehrmann J, Banati RB, Cuzner ML, Kreutzberg GW, Newcombe J. Amyloid precursor protein (APP) expression in multiple sclerosis lesions. Glia 1995; 15:141.
102. Van Der Voom P, Tekstra J, Beelen RJ, Tensen CP, Van Der Valk P, De Grot CAJ. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 1999; 154:45.
103. Zajicek J, Wing M, Skepper J, Compston A. Human oligodendrocytes are not sensitive to complement: Study of CD59 expression in the human central nervous system. Lab Invest 1995; 73:128.
104. Oleszak A, Zaczynska E, Bhattacharjee M, Butunoi C, Legido A, Katsetos CD. Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute but not in chronic multiple sclerosis. Clin Diagn Lab Immunol 1998; 5: 438.
105. van-der-Maesen K, Hinojoza JR, Sobel RA. Endothelial cell class II major histocompatibility complex molecule expression in stereotactic brain biopsies of patients with acute inflammatory / demyelinating conditions. J Neuropathol Exp Neurol 1999; 58:346.
106. Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M, Morgan BP. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: Analysis in multiple sclerosis and bacterial meningitis. J Immunol 1998; 160:3543.
107. Mayer AM. Therapeutic implications of microglia activation by lipopolysaccharide and reactive oxygen species generation in septic shock and central nervous system pathologies: A review. Medicina B Aires 1998; 58:377.
108. Bruck W, Sommermeier N, Bergmann M, Zettl U, Goebel HH, Kretzschmar HA, Lassmann H. Macrophages in multiple sclerosis. Immunobiology 1996; 195:588.
109. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions (see comments). Ann Neurol 1995; 37:424.
110. Bitsch A, da-Costa C, Bunkowski S, Weber F, Rieckmann P, Bruck W. Identification of macrophage populations expressing tumor necrosis factor-alpha mRNA in acute multiple sclerosis. Acta Neuropathol Berl 1998; 95:373.
111. Owens GP, Kraus H, Burgoon MP, Smith-Jensen T, Devlin ME, Gilden DH. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998; 43:236.
112. Traugott U, Trejo, V. Fluoxetine greatly inhibits disease progression in chronic experimental allergic encephalomyelitis (EAE) in SJL/J mice. Neurology 1997; 48:A422.
113. Traugott U. Detailed analysis of the immuomodulatory properties of Fluoxetine (Prozac) in chronic experimental allergic encephalomyelitis (EAE) in SJL/L mice. Neurology 1998; 50: A105.
114. Lujan S, Masjuan J, Roldan E, Villar LM, Gonzalez-Porque P, Alvarez-Cermeno JC. The expression of integrins on activated T-cells in multiple sclerosis: Effect of intravenous methylprednisolone treatment. Mult Scler 1998; 4:239.
115. Corsini E, Gelati M, Dufour A, Massa G, Nespolo A, Ciusani E, Milanese C, La-Mantia L, Salmaggi A. Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study. J Neuroimmunol 1997; 79:76.